Novartis achieves the First Biosimilar approval in US

06/03/2015 - 3 minutes

The Novartis company Sandoz has become the first company with a biosimilar approved by the US Food and Drug Administration (FDA) after today’s approval of Zarxio, a treatment for neutropenia.

Sandoz is the first company to receive the approval of a biosimilar in the US through the new FDA biosimilars pathway established under Biologics Price Competition and Innovation Act (BPCIA), that provides an abbreviated route for biosimilar products to enter the market.
Zarxio (filgrastim-sndz) is designated for all indications included in the reference product’s label. The approval was based on a comprehensive package of analytical, nonclinical, and clinical data, which confirmed that Zarxio is highly similar to the US-licensed reference product. The approval of Zarxio follows the unanimous positive vote in January by the Oncologic Drugs Advisory Committee (ODAC).

Carol Lynch, Global Head of Biopharmaceuticals & Oncology Injectables at Sandoz, stated: “The FDA approval of Zarxio marks a significant milestone for the United States healthcare system and for patients who might suffer from neutropenia.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member